New Study for T2D Patients currently taking Trulicity
Please fill in your details
About the Study
This study is for participants with Type 2 Diabetes currently taking Trulicity at a dose of 0.75 mg or 1.5 mg. Participants will either go on a higher dose of Trulicity or switch to Tirzepatide (Mounjaro). Mounjaro is a once-weekly injection for Type 2 Diabetes. The purpose of the study is to compare changes in A1C and weight loss.
Participants will receive the study med at no charge, and will be compensated for their time and travel.
Participant Eligibility Criteria ( To take part in the study )
- Type 2 Diabetes
- Currently taking Trulicity (0.75 mg or 1.5 mg)
- A1C between 7.0% and 9.5%
- Not using insulin